JAZZ - Jazz Pharmaceuticals plc
| Previous Close | 133.85 |
| Open | 134.37 |
| Bid | 132.93 x 1000 |
| Ask | 133.19 x 900 |
| Day's Range | 132.54 - 134.74 |
| 52 Week Range | 113.52 - 174.00 |
| Volume | 45,248 |
| Avg. Volume | 470,321 |
| Market Cap | 7.762B |
| Beta (3Y Monthly) | 0.99 |
| PE Ratio (TTM) | 12.03 |
| EPS (TTM) | 11.03 |
| Earnings Date | Nov 4, 2019 - Nov 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 170.38 |
- Simply Wall St.
Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
- Zacks
Is Jazz Pharmaceuticals (JAZZ) a Profitable Value Stock?
Jazz Pharmaceuticals (JAZZ) stock may be a good choice for value-oriented investors right now from multiple angles.
- American City Business Journals
Jazz buys Virginia biotech firm in deal valued at up to $312.5M
The company Jazz bought is developing a new treatment for a a nervous system disorder that causes rhythmic shaking.
- Zacks
Jazz (JAZZ) Acquires Cavion, Adds Movement Disorder Candidate
Jazz (JAZZ) acquires privately-held Cavion for a total consideration of $312.5 million including an upfront payment of $52.5 million and $260 million in potential clinical, regulatory and commercial milestones.
- Benzinga
The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novelion Delays Quarterly Results
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 12) GENMAB A/S/S ADR (NASDAQ: GMAB ) (IPOed July 1) Down ...
- PR Newswire
Jazz Pharmaceuticals Announces Acquisition of Cavion, Inc.
Transaction Adds Worldwide Rights to CX-8998, a Modulator of T-type Calcium Channels, for the Potential Treatment of Essential Tremor Strong Strategic Fit with a Differentiated Mechanism of Action in an ...
Motley Fool(PFNX) Q2 2019 Earnings Call Transcript
PFNX earnings call for the period ending June 30, 2019.
- Thomson Reuters StreetEvents
Edited Transcript of JAZZ earnings conference call or presentation 6-Aug-19 8:30pm GMT
Q2 2019 Jazz Pharmaceuticals PLC Earnings Call
- Zacks
Jazz Pharma (JAZZ) Q2 Earnings and Sales Beat Estimates
Jazz Pharmaceuticals (JAZZ) reports encouraging second-quarter 2019 earnings and revenues and raises its sales guidance for 2019.
- Motley Fool
Jazz Pharmaceuticals Sings a Sweet Tune in Q2
The drugmaker delivered revenue and earnings beats thanks to continued momentum for sleep disorder drug Xyrem.
- Zacks
Jazz Pharmaceuticals (JAZZ) Beats Q2 Earnings and Revenue Estimates
Jazz (JAZZ) delivered earnings and revenue surprises of 13.45% and 5.08%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Jazz Pharmaceuticals Announces Second Quarter 2019 Financial Results
Total Revenues Increased 7% to $534 Million GAAP Diluted EPS of $4.56 ; Adjusted Diluted EPS of $4.05 Launched Sunosi in Early July in the U.S. Expansion of Defitelio into Japan Following Nippon Shinyaku ...
- PR Newswire
Jazz Pharmaceuticals Advances Recombinant Crisantaspase Development Program
DUBLIN, Aug. 6, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced that the Phase 1 study of its recombinant crisantaspase molecule, JZP-458, met its efficacy and safety objectives. The company plans to initiate a single-arm, pivotal Phase 2/3 study evaluating JZP-458 as a potential treatment option for patients with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) who are hypersensitive to E. coli-derived asparaginase products. "Jazz is committed to the ALL patient community, and we are pleased to advance this development program with the goal of bringing a new treatment option to ALL and LBL patients who are hypersensitive to E. coli-derived asparaginase products as soon as possible," said Robert Iannone, M.D., M.S.C.E., executive vice president, research and development of Jazz Pharmaceuticals.
- Zacks
What's in the Cards for Bausch Health (BHC) in Q2 Earnings?
Investors are looking forward to the performance of Salix and Bausch + Lomb, and other pipeline updates, when Bausch (BHC) reports Q2 results on Aug 6.
- Zacks
Is a Beat in the Cards for Regeneron (REGN) Q2 Earnings?
Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports second-quarter 2019 results.
- Simply Wall St.
Is There An Opportunity With Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) 34% Undervaluation?
How far off is Jazz Pharmaceuticals plc (NASDAQ:JAZZ) from its intrinsic value? Using the most recent financial data...
- Zacks
Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy?
Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- TheStreet.com
Jazz (Pharmaceuticals) Has Pizzazz With Quant Upgrade and Bullish Charts
Two reasons to buy a stock are better than one. Right?
- Zacks
Will Jazz (JAZZ) Beat Estimates Again in Its Next Earnings Report?
Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- PR Newswire
Jazz Pharmaceuticals to Report 2019 Second Quarter Financial Results on August 6, 2019
DUBLIN , July 23, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2019 second quarter financial results on Tuesday, August 6, 2019 , after the close ...
- Motley Fool
3 Incredibly Cheap Healthcare Stocks
Looking for bargains? You'll definitely want to check out these dirt-cheap healthcare stocks.
- American City Business Journals
Jazz Pharmaceuticals signs multimillion-dollar deal for experimental cancer therapy
Jazz is paying $3.5 million up front, and another $203 million in contingent payments tied to hitting product development milestones, for an England company's cancer therapy program.
- Zacks
Jazz (JAZZ) Acquires Early-Stage Precision Oncology Asset
Jazz (JAZZ) acquired Redx Pharma's early stage pan-RAF inhibitor program for developing potential treatment for cancer with RAF and RAS mutations.
- Benzinga
The Daily Biotech Pulse: Jazz Buys Tumor Drug Program, Sanofi's BLA For Multiple Myeloma Drug Accepted, Positive Results For ViiV
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 9) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Athenex ...
- PR Newswire
Jazz Pharmaceuticals Acquires Pre-clinical Pan-RAF Inhibitor Program from Redx Pharma
Pan-RAF Program adds an Early Stage, Innovative, Precision Oncology Asset to Jazz Pharmaceuticals' Growing R&D Portfolio Redx to Receive $3.5 Million Upfront, up to $203 Million in Milestone Payments and ...
